Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

This study has been terminated.
(Lack of efficacy)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
David M. Brown, M.D., Greater Houston Retina Research
ClinicalTrials.gov Identifier:
NCT00423189
First received: January 16, 2007
Last updated: February 5, 2016
Last verified: February 2016

January 16, 2007
February 5, 2016
January 2007
January 2009   (final data collection date for primary outcome measure)
Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of >15 Letters at 12 Months) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
Visual Acuity was measured by ETDRS by certified refractionists in certified lanes at 12 months. Visual Acuity was not measured by ETDRS at 6 months.
Best-corrected ETDRS visual acuity at 3 and 12 month time points (gain or loss of >15 letters at 12 months)
Complete list of historical versions of study NCT00423189 on ClinicalTrials.gov Archive Site
  • Number of Intravitreal Injections With Ranibizumab Needed by Patients at 12 Months [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    Number of intravitreal injections with ranibizumab needed by patients at 12 months was not determined due to lack of efficacy.
  • OCT 3 Macular Thickness Improvement (Baseline-1month, 2months, 3months, 6months &12 Months) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    OCT 3 macular thickness improvement at Baseline-1month, 2months, 3months, 6months &12 months was not determined due to lack of efficacy.
  • Choroidal Perfusion as Assessed by ICG Angiography at 1, 2, 3, 6, and 12 Months [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    Choroidal perfusion as assessed by ICG angiography at 1, 2, 3, 6, and 12 months was not determined due to lack of efficacy
  • Safety of Combination Therapy With Verteporfin PDT and ITV Ranibizumab [ Time Frame: 1 Year ] [ Designated as safety issue: Yes ]
    Safety of combination therapy with verteporfin PDT and ITV ranibizumab was not determined due to lack of efficacy.
  • Number of Intravitreal Injections With Ranibizumab Needed by Patients at 12 Months
  • OCT 3 Macular Thickness Improvement (Baseline-1month, 2months, 3months, 6months &12 Months)
  • Choroidal Perfusion as Assessed by ICG Angiography at 1, 2, 3, 6, and 12 Months
  • Safety of Combination Therapy With Verteporfin PDT and ITV Ranibizumab
Not Provided
Not Provided
 
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Lucentis Utilizing Visudyne (LUV Trial)-- Reduced Fluence Photodynamic Therapy With Visudyne Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
The PDT/Lucentis trial will be a Phase IV comparative trial comparing the use of combination therapy with ITV ranibizumab and verteporfin PDT to ITV ranibizumab alone in patients with exudative AMD.
The PDT/Lucentis trial will be a Phase IV comparative trial comparing the use of combination therapy with ITV ranibizumab and verteporfin PDT to ITV ranibizumab alone in patients with exudative AMD. Patients will be randomized to one of three groups. All patients will receive three consecutive monthly treatments with ITV ranibizumab. Patients randomized to group I will receive only ITV ranibizumab. Patients randomized to group II will also receive one treatment with reduced fluence (20% fluence) verteporfin PDT at day 0. Patients randomized to group III will also receive one treatment with reduced fluence (40% fluence) vPDT. All patients will also be evaluated for possible retreatment with ranibizumab according to established criteria. Thirty patients (ten per group) will be recruited from one U.S. sites in a 6-month period. Randomization will occur at the time of entry into the study. Follow-up will continue until month 12 (from day 0) in all subjects.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Age-Related Macular Degeneration
  • Drug: Ranibizumab (Lucentis)
    as needed, one intravitreal injection of 0.50mg ranibizumab
    Other Names:
    • PDT
    • Photodynamic Therapy
  • Drug: 0.5mg ranibizumab
    as needed, one intravitreal injection of 0.50mg ranibizumab
    Other Name: lucentis
  • Active Comparator: Ranibizumab only
    drug - intravitreal ranibizumab
    Interventions:
    • Drug: Ranibizumab (Lucentis)
    • Drug: 0.5mg ranibizumab
  • Experimental: 40% fluence PDT/procedure
    40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
    Interventions:
    • Drug: Ranibizumab (Lucentis)
    • Drug: 0.5mg ranibizumab
  • Experimental: 20% fluence photodynamic therapy
    20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
    Interventions:
    • Drug: Ranibizumab (Lucentis)
    • Drug: 0.5mg ranibizumab

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
January 2009
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 55 years
  • Subfoveal neovascular membrane confirmed by fluorescein angiography and or ICG
  • Visual acuity not better than 20/32 and not worse than 20/320 by ETDRS refraction

Exclusion Criteria:

  • Any previous vitrectomy in study eye (posterior or anterior associated with vitreous loss in cataract surgery)
  • Intracapsular cataract extraction (posterior capsule needs to be present)
  • Previous treatment with ranibizumab
  • Previous treatment with pegaptanib
  • Previous treatment with ITV triamcinolone
  • Any previous treatment with photodynamic therapy
  • Previous history of retinal detachment in study eye
  • Any previous radiation treatments to head/ neck
  • Significant cardiovascular disease or cancer that would prevent follow-up visits or completion of the 12 month study
  • Prior enrollment in any study for AMD in the study eye
  • Participation in another simultaneous medical investigator or trial
  • Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment or macular hole.
  • Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the study period
  • Aphakia or absence of the posterior capsule in the study eye
  • Previous violation of the posterior capsule is also excluded unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
  • History of idiopathic or autoimmune uveitis in either eye
  • Significant structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s)
  • Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or by OCT
  • Ocular inflammation (including trace or above) in the study eye
  • Uncontrolled glaucoma (defined as intraocular pressure ≥30 mm Hg despite treatment with anti- medications) or previous filtration surgery in the study eye
  • Infectious blepharitis, keratitis, scleritis, or conjunctivitis (in either eye) or current treatment for serious systemic infection
  • Spherical equivalent of the refractive error in the study eye of more than -8 diopters myopia (For patients who have had refractive or cataract surgery in the study eye, pre-operative spherical equivalent refractive error of more than -8 diopters myopia is not allowed)

Systemic Conditions

  • Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during the screening period
  • Uncontrolled diabetes mellitus
  • Renal failure requiring dialysis or renal transplant
  • Premenopausal women not using adequate contraception
  • Previous participation in other studies of investigational drugs (excluding vitamins and minerals) within 3 months preceding Day 0
  • History of other disease, metabolic dysfunction, physical examination finding, or other findings giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications
  • INR ≥ 3.0 (e.g. due to current treatment with warfarin). The use of aspirin is not an exclusion.

Other

  • History of allergy to fluorescein, not amenable to treatment
  • History of allergy to shellfish
  • History of allergy to intravenous iodine
  • History of allergy to indocyanine green
  • Inability to obtain fundus photographs or angiograms of sufficient quality to be analyzed and graded by the central reading center
  • Inability to comply with study or follow up procedures
  • History of allergy to humanized antibodies or any component of the ranibizumab formulation
Both
55 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00423189
LUV
Yes
Not Provided
Not Provided
David M. Brown, M.D., Greater Houston Retina Research
David M. Brown, M.D.
Novartis Pharmaceuticals
Principal Investigator: David M Brown, M.D. Vitreoretinal Consultants
Greater Houston Retina Research
February 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP